Niche Anti-Infectives Cerexa specializes in developing novel anti-infective therapies targeting serious and life-threatening infections, presenting a clear focus area for potential partnerships or product acquisitions within high-need microbial sectors.

Growing Financial Base With a funding of 50 million dollars and annual revenue estimated between 10 to 25 million dollars, Cerexa demonstrates financial stability and scalability opportunities for collaboration or investment-focused initiatives.

Strategic Parent Support As a wholly-owned subsidiary of Forest Laboratories, Cerexa benefits from extensive industry resources and expertise, making it a strategic partner for companies seeking to expand their antimicrobial portfolio or co-develop innovative treatments.

Targeted Market Niche Operating in the biotechnology research sector with a specialized focus on anti-infective therapies, Cerexa offers a market segment with growing demand for innovative solutions, ideal for sales targeting infectious disease specialists and healthcare institutions.

Smaller but Specialized With 51-200 employees, Cerexa is a compact organization focused on niche therapeutics, indicating agility and openness to forming collaborations designed to accelerate development and commercialization of new anti-infective agents.